AllSci News
FDA adds 3 months to review of Eisai's Leqembi Iqlik subcutaneous formulation for early Alzheimer's
The US FDA has extended its review of a supplemental application for Leqembi Iqlik (lecanemab-irmb), pushing the PDUFA date for the subcutaneous...
Trinity College Dublin researchers identify NK cell dysfunction in neovascular AMD
Researchers at Trinity College Dublin in Ireland, working with collaborators at the Royal Victoria Eye and Ear Hospital and using population data from the...
Pfizer pulls development of Trillium-acquired anti-CD47 inhibitor maplirpacept
Pfizer has terminated its Phase I/II study evaluating maplirpacept (PF-07901801), an anti-CD47 innate immune checkpoint inhibitor, in combination with...
Nuvation adds data to sNDA for Ibtrozi in ROS1-positive NSCLC
Nuvation Bio submitted a supplemental New Drug Application (sNDA) to the US FDA for Ibtrozi (taletrectinib), its next-generation ROS1 inhibitor, seeking to...
FDA aligns with Pierre Fabre on Ebvallo resubmission path for EBV+ PTLD treatment
Pierre Fabre Pharmaceuticals has announced it has aligned with the US FDA on a potential path forward for resubmission of the Biologics License Application...
Bayer's iodine 124 evuzamitide meets primary endpoints in Phase III cardiac amyloidosis imaging trial
Bayer has reported that iodine 124 evuzamitide met both primary endpoints in the Phase III REVEAL study, demonstrating sufficient sensitivity and...
GSK licenses Halozyme Enhanze platform for subcutaneous ADCs
GSK (NYSE: GSK) has licensed Halozyme Therapeutics' (Nasdaq: HALO) Enhanze drug delivery platform for subcutaneous formulations of multiple oncology...
Angelini Pharma acquires Catalyst Pharmaceuticals for USD 4.1b to enter US market, expand rare disease portfolio
Italy-based Angelini Pharma S.p.A. has entered into a definitive agreement to acquire Catalyst Pharmaceuticals (Nasdaq: CPRX) for USD 31.50 per share in...
Travere Therapeutics raises USD 475m in convertible debt offering
San Diego-based Travere Therapeutics (Nasdaq: TVTX) announced an upsized convertible debt financing on May 6, 2026, structured primarily to retire a portion...
Waiv partners with Daiichi Sankyo on AI biomarkers for undisclosed ADC program
Waiv will apply its computational pathology platform to support biomarker discovery in an undisclosed antibody-drug conjugate (ADC) program at Daiichi Sankyo (TSE:…
INmune Bio and Anthony Nolan expand CORDStrom MSC platform across RDEB, oncology, and inflammatory diseases
INmune Bio (Nasdaq: INMB), the Boca Raton, Florida-based clinical-stage biotechnology company, and Anthony Nolan, the UK stem cell charity, have signed an…
Viridian Therapeutics raises USD 350m in convertible notes and equity offerings
Waltham, Massachusetts-based Viridian Therapeutics, Inc. (Nasdaq: VRDN) announced concurrent upsized public offerings totaling USD 350 million in aggregate...
GSK puts up USD 55m for SiranBio's ALK7 siRNA targeting cardiometabolic disease
GSK (NYSE: GSK) has licensed SA030, a Phase I siRNA oligonucleotide targeting activin receptor-like kinase 7 (ALK7), from Suzhou-based SiranBio in a...
Cartography Biosciences secures strategic investment from Samsung Ventures for oncology pipeline
South San Francisco-based Cartography Biosciences has received a strategic equity investment from Samsung Ventures to support the advancement of its...
Partner Therapeutics’ zenocutuzumab bispecific antibody receives FDA priority voucher for cholangiocarcinoma
Partner Therapeutics, Inc. (PTx), a private biotechnology company headquartered in Lexington, Massachusetts, announced receipt of an FDA Commissioner’s National Priority Voucher (CNPV)…
The AllSci Brief
Free, systematic R&D and deal news. Daily.